| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Loss before income taxes | -40,966 | -55,392 | -38,437 | -43,619 |
| Income tax expense | 0 | 1,254 | 165 | 90 |
| Loss before equity in net losses of joint venture | -40,966 | -56,646 | -38,602 | -43,709 |
| Equity in net losses of joint venture | 0 | 0 | - | -260 |
| Net loss | -40,966 | -56,646 | -38,602 | -43,969 |
| Net loss per share, basic (in dollars per share) | -0.3 | -0.5 | -0.36 | -0.42 |
| Net loss per share, diluted (in dollars per share) | -0.3 | -0.5 | -0.36 | -0.42 |
| Weighted average shares outstanding, basic (in shares) | 136,446,534 | 113,743,358 | 107,202,374 | 104,824,877 |
| Weighted average shares outstanding, diluted (in shares) | 136,446,534 | 113,743,358 | 107,202,374 | 104,824,877 |
ADC Therapeutics SA (ADCT)
ADC Therapeutics SA (ADCT)